Wisconsin Alumni Research Foundation

Mycogen Plant Science, Inc.

Lubrizol Genetics, Inc.

Other

Paul G Ahlquist

Roy C French

Paul F Lambert

Dohun Pyeon

Robert F Sacher

Michael A Newton

Hao Shun Huang

Masayuki Ishikawa

Thomas L German

John T Stout

Robert L Gilbertson

Douglas P Maxwell

Juana Diez

Duane B Price

Michael A Krol

Lada Rasochova

Shane Pearce

Roland R Rueckert

Wai-Ming Lee

B Duane Price

Steven F Hanson

Hang T Luu

A method of inhibiting double-stranded DNA virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors. In another embodiment, the method involves administering an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors to a susceptible tissue or cell.

Method and compositions for inhibition of double stranded DNA viruses

Disclosed herein are novel methods and materials directed to transforming a host cell and expressing exogenous RNA therein. Specifically disclosed are DNA-launching platforms used to introduce a replicating viral segment attached to an exogenous polynucleotide into a cell, whereby the exogenous polynucleotide is expressed in said cell and confers a detectable trait.

Expression cassette for transformation comprising a modified viral sequence driven by a suitable promoter

A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell.

Drugs to prevent HPV infection

Cervical cancer cells and HPVhead and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.

Biomarkers for human papilloma virus-associated cancers

Drugs to treat HPV infection

Biomarkers for human papilloma virus-associated cancer

An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1 gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 genes, MAB2 genes, MAB3 genes or OLE1 genes, homologs of these genes, related genes and combinations of these genes and homologs.

Yeast genes that affect viral replication

A method of producing a packaged DNA sequence is disclosed. In one embodiment, the method comprises the steps of: (a) selecting a DNA sequence to be packaged and a papillomaviral capsid sequence, wherein the DNA sequence to be packaged is between 7 Kb-8.5 Kb, (b) co-transfecting the products of step (a) into transfectable cells, wherein the DNA sequence is packaged, and (c) purifying packaged particles.

Production of packaged DNA sequences

The invention involves production of transgenic plants containing DNA encoding AC1/C1 wildtype and mutant sequences that negatively interfere in trans with geminiviral replication during infection. The transgenic plants produced by the invention are resistant to viral infection.

Transgenic plants expressing mutant geminivirus AC1 or C1 genes

A method of synthesizing particles containing nucleic acid sequences is disclosed. This method comprises the steps of introducing a non-endogenous packageable nucleic acid sequence and a sequence encoding a suitable non-endogenous capsid protein into yeast cells and inducing particle assembly, wherein at least one nucleic acid is encapsidated. Preferably, the particle is an infectious virion and the method additionally comprises the step of inducing viral nucleic acid replication before particle assembly. A method of replicating an animal or Nodaviridae virus nucleic acid sequences in yeast is also disclosed.

Method of producing particles containing nucleic acid sequences in yeast

A +strand RNA viral transformation of host organisms with foreign RNA, and expression of said foreign RNA. The foreign RNA is inserted into an infective RNA viral segment containing replication elements, and allowed to infect the host organism. The invention is exemplified utiliing brome mosaic RNA modified to contain a gene coding for chloramphenicol acetyl transferase (CAT) in the transformation of barley protoplasts.

RNA transformation vector

A recombinant RNA virus is provided allowing encapsidation of genetically engineered viral sequences in heterologous, preferably rod-shaped coat, protein capsids. Since icosahedral viruses are limited in the amount of RNA they can carry, and rod-shaped viruses are expansible, this invention allows the size of recombinant virus RNA components to be increased (or decreased). Methods of making and using such recombinant viruses are also provided, specifically with respect to the transfection of plants to bring about genotypic and phenotypic changes.

Plasmid encoding hybrid RNA virus

A subgenomic promoter of a positive strand RNA virus is disclosed which directs the amplified expression of a structural gene in plant tissue. The core region and an upstream activating domain of the subgenomic promoter are identified. This promoter can be utilized in a modified virus, or in an appropriate engineered recombinant DNA derivative which may be chromosomally integrated or maintained as an episome in transformed cells.

Growing community of inventors

Madison, WI, United States of America

Paul G Ahlquist